Patent ID: 11965875
Assignee: ADLAI NORTYE BIOPHARMA CO., LTD.
Field: Measurement (Instruments)
Classification: CPC G | IPC C  G

Claim 4:
5. The method according to claim 4, wherein the phenotype of T cells comprises: a ratio of the T cells in tumor tissue, the proliferative capacity of the T cells, the activity of the T cells, the expression level of interleukin-2 (IL-2) in the T cells, the expression level of tumor necrosis factor α (TNFα) in the T cells, the expression level of granzyme in the T cells, the expression level of interferon-γ (IFNγ) in the T cells, and/or the expression level of programmed death receptor-1 (PD1) in the T cells;
wherein the phenotype of dendritic cells comprises: a ratio of the dendritic cells in tumor tissue, the proliferative capacity of the dendritic cells, the activity of the dendritic cells, the expression level of co-stimulatory molecules CD80 and CD86 in the dendritic cells, and/or the expression level of PD-L1 in the dendritic cells;
wherein the phenotype of NK cells comprises: a ratio of the NK cells in tumor tissue, the proliferative capacity of the NK cells, the activity of the NK cells, the expression level of C-type lectin receptor family member A (NKG2A) in the NK cells, the expression level of granzyme in the NK cells, and/or the expression level of killer cell immunoglobulin-like receptor KIR in the NK cells; and/or
wherein the phenotype of macrophages comprises: a ratio of the macrophages in tumor tissue, the proliferative capacity of the macrophages, the activity of the macrophages, and/or a ratio of M1-type macrophages to M2-type macrophages in tumor tissue.